Richard C.E. Morgan, Chairman
Richard C.E. Morgan is Chief Executive Officer of Amphion Innovations plc, a London and New York based venture capital firm. Over the course of his career, Mr. Morgan has been directly involved in the start-up and development of more than 35 companies in the information technology, healthcare, and biotechnology industries. These include Celgene, which Mr. Morgan co-founded in 1987 and where he was on the board for over 20 years, serving on the executive committee and chairing the compensation committee until he stepped down in 2008. He was chairman for many years of MediSense, through its IPO and later through the completion of its acquisition by Abbott Labs for about $950 million. Mr. Morgan was also a board member and lead director of Sequus for many years through its acquisition by Alza for about $700 million. He was also formerly chairman of Quidel for many years and a board member of a number of private companies. Mr. Morgan was the Managing General Partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP) a position which he retains, although the partnership is no longer active. Before joining Wolfensohn, Mr. Morgan spent 15 years with Schroders plc, a British merchant bank, where he was a member of the Board of the merchant bank and head of the Schroder Strategy Group, which he founded. Mr. Morgan, a British citizen, was raised in Kenya and educated in England. He graduated with a B. Engineering First Class Honors from the University of Auckland, New Zealand. In 1982 he completed the Advanced Management Program at the Harvard Business School. He is currently also Chairman of Axcess International, Inc., FireStar Software Inc., PrivateMarkets, Inc., and WellGen, Inc.